➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
Dow
Colorcon
McKinsey
Harvard Business School

Last Updated: July 26, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,664,215


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,664,215 protect, and when does it expire?

Patent 8,664,215 protects LASTACAFT and is included in one NDA.

This patent has forty-six patent family members in thirty countries.

Summary for Patent: 8,664,215
Title:Ocular allergy treatments with alcaftadine
Abstract: Compositions, kits, and methods for the treatment or prevention of ocular allergies and inflammation and the symptoms thereof containing alcaftadine or a pharmaceutically acceptable salt thereof.
Inventor(s): Ingerman; Avner (Scarsdale, NY), Janssens; Frans (Bonheiden, BE), Megens; Anton (Beerse, BE), Abelson; Mark B. (Andover, MA)
Assignee: Vistakon Pharmaceuticals, LLC (Jacksonville, FL)
Application Number:11/690,954
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,664,215
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,664,215

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan LASTACAFT alcaftadine SOLUTION/DROPS;OPHTHALMIC 022134-001 Jul 28, 2010 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial METHOD FOR PREVENTING ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,664,215

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 060278 ⤷  Free Forever Trial
Argentina 111697 ⤷  Free Forever Trial
Australia 2007234957 ⤷  Free Forever Trial
Brazil PI0710085 ⤷  Free Forever Trial
Canada 2648115 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Express Scripts
Harvard Business School
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.